Loading market movers...

TransCon IL-2 β/γ

Phase 2

Ascendis Pharma A/S (ASND)

00%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Aug '27

ASNDPhase 2$14.2B

TransCon IL-2 β/γ Phase 2 Est. Readout

TransCon IL-2 β/γ• Advanced Solid Tumor320

Aug 2027~Confirmed

00%

Competitive Landscape

6 competitors in Advanced Solid Tumor

ANROLM-302 Injection

View Full Landscape

Drug Information

Target Indication

Advanced Solid Tumor

Clinical Trial

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ASND

Ascendis Pharma A/S

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

TransCon hGHPhase 3

Growth Hormone Deficiency, Pediatric

Once weekly subcutaneous injection of TransCon hGHPhase 3

Growth Hormone Deficiency, Pediatric

LonapegsomatropinPhase 3

Growth Hormone Deficiency

TransCon CNPPhase 3

Achondroplasia

ACP-001 (TransCon hGH)Phase 2

Adult Growth Hormone Deficiency

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts